Vascular disruption agents and uses thereof
AssigneeGenentech, Inc.
InventorAvi J. Ashkenazi
Life of this patent
Estimating the term…
Abstract
Uses of Apo2L/TRAIL polypeptides and death receptor agonist antibodies to disrupt tumor associated vasculature are provided. Methods of treating cancer in mammals, kits, and articles of manufacture are also provided.
Claims22
A method of disrupting tumor associated vasculature in mammalian tissue or cells, comprising exposing said tissue or cells to a therapeutically effective amount of Apo2L/TRAIL polypeptide or death receptor agonist antibody.
A method of treating cancer in a mammal, comprising administering to said mammal a therapeutically effective amount of Apo2L/TRAIL polypeptide or death receptor agonist antibody to disrupt tumor associated vasculature in the mammal.
Use of Apo2L/TRAIL polypeptide or death receptor agonist antibody in the manufacture of a medicament for disrupting tumor associated vasculature or for the treatment of cancer.
The use of Apo2L/TRAIL polypeptide or death receptor agonist antibody in the manufacture of a kit for use in treating cancer.
A kit for use in the treatment of cancer, comprising (a) a container comprising Apo2L/TRAIL polypeptide or death receptor agonist antibody and a pharmaceutically acceptable carrier or diluent within the container;
- and (b) a package insert with instructions for administering said Apo2L/TRAIL polypeptide or death receptor agonist antibody to disrupt tumor associated vasculature in a human patient having cancer.
Dependencies are inferred from the claim text.